An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A medical review paper looked at what surgeons and patients should know when people who are taking GLP-1 drugs — the same class as Ozempic and Wegovy — have plastic surgery. The paper pulls together existing advice and research to suggest how to handle these medications around the time of an operation. It’s not reporting a brand-new experiment; it’s more of a practical guide for doctors based on current evidence and expert opinion. GLP-1 receptor agonists (that’s a mouthful) are medicines that act like a natural gut hormone called GLP-1. In plain terms: they make you feel less hungry, help control blood sugar, and slow how fast your stomach empties. Drugs like semaglutide and liraglutide are in this family and are commonly used for type 2 diabetes and for weight loss. They’re injected and can lead to weight loss and reduced appetite, which is why you might hear about them a lot lately. The review summarizes what the literature and surgeons recommend about using these drugs around surgery. Key points are that because GLP-1 drugs slow stomach emptying, they can increase the risk of nausea, vomiting, and aspiration (when stomach contents get into the lungs) during anesthesia. There are also concerns about blood sugar control — these drugs affect glucose levels, so anesthesia teams need to plan for that. Most of the recommendations come from observational studies, small case series, or expert consensus rather than large randomized trials. That means the guidance reflects real-world experience and caution, not definitive proof. Why this matters is simple: more people taking GLP-1 drugs are having elective surgeries like cosmetic procedures. Surgeons, anesthesiologists, and patients need a plan to reduce risks. The practical takeaways are that teams might ask patients to stop their GLP-1 drug for a short period before surgery, adjust diabetes medications, and monitor blood sugars closely. For cosmetic patients using these drugs for weight loss, it’s important both for safety under anesthesia and for proper healing to communicate medication use well ahead of time. There are caveats. Stopping GLP-1 drugs can cause a return of appetite or changes in blood sugar, so people with diabetes especially need careful replacement plans. The evidence base is not robust; recommendations vary and are being updated as doctors gain more experience. Some patients may be at higher risk from stopping therapy, and not every surgery has the same considerations. Regulatory status isn’t an issue here — these drugs are approved for diabetes and some for weight loss — but their perioperative handling isn’t standardized. Bottom line: If you’re on a GLP-1 drug and planning plastic surgery, tell your surgical team early so they can make a plan; temporary changes to your medication and closer monitoring around the operation are commonly advised, but the exact approach depends on individual risk and doctor judgment.
Source: Cureus